Patents by Inventor Peter Richardson

Peter Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220237374
    Abstract: A system and method for identifying relevant content from other documents and presenting candidate documents/content in a document authoring application is described. A computer-implemented method includes performing an analysis of text of a document being authored by a user with a document authoring application, searching a document library for content elements and documents based on the analysis of the text, identifying candidate documents and candidate content based on the searching, presenting a list of candidate documents or candidate content with the document authoring application, receiving a selection of a candidate document or candidate content from the list in the document authoring application, and including an instance of the selected candidate document or candidate content in the document.
    Type: Application
    Filed: March 26, 2021
    Publication date: July 28, 2022
    Inventors: Benjamin Gustav WILDE, Ransom Lloyd RICHARDSON, Richard Malcolm BANKS, Manoj SHARMA, Zeyu WU, Matthew Stephen HOWARD, Sudarshan SUNDAR, Lyndsy Marie STOPA, Yi ZHENG, Jacob Lee SANCHEZ, Aleksandr POLYAKOV, Jason Peter CAMPOLI, Gregory Alan HOWARD, Paul Anthony SCUDIERI
  • Patent number: 11396003
    Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: July 26, 2022
    Assignees: Randox Laboratories, Ltd., Randox Teoranta
    Inventors: Peter Fitzgerald, John Lamont, Ivan McConnell, Elouard Benchikh, Deepesh Upadhyay, Ciaran Richardson
  • Patent number: 11383216
    Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: July 12, 2022
    Assignees: Randox Laboratories, Ltd., Randox Teoranta
    Inventors: Peter Fitzgerald, John Lamont, Ivan McConnell, Elouard Benchikh, Deepesh Upadhyay, Ciaran Richardson
  • Patent number: 11369616
    Abstract: The invention relates to a combination of CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1, 4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide and an immune checkpoint inhibitor, and the use of the same in the treatment of tumours and/or cancers.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 28, 2022
    Assignee: PROXIMAGEN, LLC
    Inventor: Peter Richardson
  • Patent number: 11311552
    Abstract: The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers. The invention also relates to combination treatments with irradiation and/or a chemotherapeutic agent for use in the treatment of cancer.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 26, 2022
    Assignee: Proximagen, LLC
    Inventors: Peter Richardson, Jacqueline Mary Walling, Claudio Festuccia
  • Patent number: 11304992
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 19, 2022
    Assignee: MANNKIND CORPORATION
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20210284805
    Abstract: A composition of matter useful in an electrolyte, comprising a polymer including: a repeat unit, the repeat unit including a backbone section; and a side chain attached to the backbone section, wherein the side chain includes a ligand moiety configured to ionically bond to a lithium ion. The polymer has a glass transition temperature (e.g., less than room temperature) wherein the polymer is in a solid state during operation of a lithium ion battery comprising an electrolyte including the polymer.
    Type: Application
    Filed: March 3, 2021
    Publication date: September 16, 2021
    Applicant: The Regents of the University of California
    Inventors: Rachel A. Segalman, Craig J. Hawker, Raphaele Clement, Javier Read de Alaniz, Nicole Michenfelder-Schauser, Peter Richardson, Andrei Nikolaev, Caitlin Sample, Hengbin Wang
  • Publication number: 20210138040
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 13, 2021
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20210069189
    Abstract: Treatment of Neurodegenerative Diseases Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), are described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting c-Abl, and inhibiting NF?B activation, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of c-Abl, and an inhibitor of NF?B activation.
    Type: Application
    Filed: September 5, 2018
    Publication date: March 11, 2021
    Inventors: Peter Richardson, David Sheppard
  • Publication number: 20200397764
    Abstract: This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 24, 2020
    Inventors: MARTYN PRITCHARD, Peter Richardson
  • Publication number: 20200386403
    Abstract: A fluid injection element is disclosed, especially for a furnace or a burner of a furnace, having a pipe and a shroud element, such that the shroud element circumferentially surrounds an axial section of the pipe extending from an axial end of the pipe, such that at least one cavity is provided at the shroud element, and the at least one cavity is in fluid communication with an interior of the pipe and the at least one cavity extends to an opening at an axial end of the shroud element.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 10, 2020
    Inventors: Andrew Peter Richardson, Martin Adendorff, Curtis Lee Bermel, Nick Marco
  • Patent number: 10857207
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 8, 2020
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Publication number: 20200281937
    Abstract: The invention relates to the use of the CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide or a pharmaceutically acceptable salt thereof in the treatment of cancers of the breast, bladder, colon, rectum and liver.
    Type: Application
    Filed: March 9, 2018
    Publication date: September 10, 2020
    Applicant: Proximagen, LLC
    Inventor: Peter RICHARDSON
  • Publication number: 20200147219
    Abstract: A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 14, 2020
    Inventors: Peter Richardson, Robert A. Baughman, Donald Costello
  • Publication number: 20200146981
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Publication number: 20200147180
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 14, 2020
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Publication number: 20190167580
    Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Inventors: Peter Richardson, Robert A. Baughman, Andrea Leone-Bay, Donald Costello
  • Patent number: 10224717
    Abstract: Embodiments of the present invention produce and define a relationship between local voltage and power measurements at a node of an electrical network and system conditions on a remote branch of the network. These local measurements are used to determine an optimal voltage set point at the node that, if realized by a reactive power resource, would affect the flow of reactive power or line current at one or more particular remote branches of the power system in a manner captured by the derived relationship. The change in reactive power required to obtain this voltage set point is also calculated based on local measurements.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 5, 2019
    Assignee: Univ. College Dublin, Nat'l. Univ. of Ireland
    Inventors: Conor Murphy, Andrew Keane, Peter Richardson
  • Publication number: 20190000861
    Abstract: The invention relates to a combination of CXCR4 antagonist 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide and an immune checkpoint inhibitor, and the use of the same in the treatment of tumours and/or cancers.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 3, 2019
    Inventor: Peter Richardson
  • Publication number: 20180360808
    Abstract: This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicant: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Martyn PRITCHARD, Peter RICHARDSON